There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .
A 12‐week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia
Objective . To analyze the effect of intravenous ferrous sucrose compared with oral ferrous sulphate on hematological parameters and quality of life in women with postpartum anemia . Design . Open r and omised controlled trial . Setting . Multicentre study comprising five obstetrical departments in Norway . Population . Hundred and twenty‐eight postpartum women with hemorrhagic anemia ( Hb between 6.5 g/100 ml and 8.5 g/100 ml ) . The intervention group ( 59 women ) received 600 mg iron sucrose intravenously followed by 200 mg iron sulphate daily from week 5 . The control group ( 70 women ) were given 200 mg iron sulphate daily . Methods . R and omisation and start of treatment occurred within 48 hours of the delivery . Participants were followed up at 4 , 8 and 12 weeks . Main outcome measures . Hemoglobin , ferritin and quality of life assessed with the Medical Outcomes Study Short Form 36 ( SF‐36 ) and the Fatigue Scale . Results . After 4 weeks the mean hemoglobin values in both groups were similar ( 11.9g/100ml vs. 12.3g/100ml , p = 0.89 ) . The mean serum ferritin value after 4 weeks was significantly higher in the intervention group with 13.7μg/L vs. 4.2μg/L in the control group ( p<0.001 ) . At 8 and 12 weeks the hematological parameters were similar . The total fatigue score was significantly improved in the intervention group at week 4 , 8 and 12 , whereas SF‐36 scores did not differ . Conclusion . Women who received 600 mg intravenous iron sucrose followed by st and ard oral iron after four weeks , replenished their iron stores more rapidly and had a more favorable development of the fatigue score indicating improved quality of life
There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .